Tweed Inc., a wholly-owned subsidiary of Canopy Growth Corporation (TSX:WEED) today announced that it has completed an intensive process of sourcing a diverse genetic seed bank and legally importing it into Canada. Tweed will begin selling cannabis seeds to authorized home growers under the Access to Cannabis for Medical Purposes Regulations in early March.
Tweed has long supported patients’ right to grow their own cannabis and is proud to be able to support those who would prefer to grow their own medical supply. Tweed is only the second producer in Canada to offer a seed option and will also offer a wide variety of dried cannabis and cannabis oil products to authorized grow at home customers as a reliable interim supply during the months it takes home growers to produce their medicine. The Company will also offer seed customers will a one-time $25 discount that can be used towards the purchase of any Tweed cannabis product.
Kevin Furet, Tweed’s Master Grower and an award-winning breeder in his own right, curated a collection of genetics with lineages originating all around the world. The resulting Tweed HomeGrow Collection is made up of ten seed types designed to meet the diverse needs of patients.
“I was aiming for quality and diversity in this collection,” said Furet. “Medical cannabis patients have diverse needs so I wanted to create a collection that matched that diversity. I see ten options as a starting point that we can build on using our own cross breeding capabilities in our custom breeding area.”
The same seeds used in the HomeGrow collection will be grown out in Tweed’s breeding facility to produce proprietary genetics that can be sold as seed or as finished products. Announced late last year, the breeding area is a first in Canada and will allow Tweed to crossbreed existing genetics for all registered customers, including home growers.
Health Canada provides authorization for home production licenses. Interested individuals can visit the Health Canada website for more information on obtaining an authorization.
UPCOMING DEC. 1 DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Aurora Cannabis Inc. – ACB
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Aurora Cannabis Inc. (NYSE: ACB) from February 13, 2020 through September 4, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Aurora Cannabis Inc. investors under the federal securities laws.
The Israeli cannabis market is picking up with a new supply deal from a Canadian producer.
Also this week, new data showed sales of Canadian cannabis edible products may be stalling.
The Israeli cannabis market is picking up as a Canadian producer announced a new supply deal in the country.
Also this week it was shown the sales of Canadian cannabis edible products may be stalling, according to new data.
Portnoy Law Firm: Credit Acceptance Corporation, Aurora Cannabis, Inc., and Loop Industries, Inc. Investors Have Limited Amount of Time Before Class Action Deadline
The Portnoy Law Firm advises investors that class action lawsuits have been filed on behalf of investors in the following publicly traded companies. Shareholders interested in taking an active role in these cases have until the deadlines indicated below to petition the court. There is no cost or obligation to you. See below for more information on these cases.
Credit Acceptance Corporation investors (NASDAQ: CACC); December 1, 2020 deadline, click here to join .
Khiron Plans to Launch Its Zerenia Medical Cannabis Clinic Strategy in Mexico; Applauds Mexican Senate Approval of Legislation for Cannabis in Mexico
- On November 19 , the Mexican Senate passed comprehensive adult-use cannabis legalization, moving Mexico towards becoming one of the few countries to legalize cannabis nationally
- On March 31, 2020 , the Company entered into an agreement with Tecnologico de Monterrey , the leading university in Mexico , to educate physicians across Latin America , in advance of the impending regulations in Mexico
- To date, close to 550 LatAm physicians have obtained their diploma accrediting completion of Khiron’s medical education program
- The Company plans to deploy its ZereniaTM medical cannabis clinics and telehealth strategy in Mexico , building on the success of its vertical integration strategy in Colombia
- Expanding the Zerenia clinic strategy will build on the Company’s Colombia knowledge and proven distribution capabilities, with rapid telehealth service adoption and over 5,600 medical cannabis scripts filled to date
- Mexico represents one of the largest potential markets for medical cannabis in the world and is anticipated to reach $1.2bn USD by 2028 (Prohibition Partners).
- Company to release Q3 2020 financials and host webcast on Tuesday, December 1st
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe welcomes the passing of adult-use cannabis legislation by the Mexican Senate, which moves the country closer to a legalized cannabis market, and towards provision for medical cannabis products. Khiron has had a presence in Mexico since 2018 and has been working with doctors and medical institutions to develop a deep understanding of the market.